Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Alector, Inc.NASDAQ: ALEC

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns negative

Q1 FY2026 Accumulated OCI was -$104K, compared with $191K a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -154.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$104K-162.7% QoQ
Last fiscal yearDec 2025
$166K-36.4% YoY
Year agoMar 2025
$191K-154.5% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-154.5%——
1 year-36.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
166K USD
Year-over-year change
-36.4%

Accumulated OCI vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -154.5% is the 4th highest of 7, against a peer median of -154.2%.
  • Accumulated OCI amounts to 0.0% of total assets for ALEC, versus a peer median of 0.0%.
ALEC Competitors
Accumulated OCI for ALEC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$21K USD+40.0%—0.0%
IRDOpus Genetics, Inc.Mar 2026$0 USD——0.0%
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
PEPGPepGen Inc.Mar 2026-$59K USD-168.2%—0.0%
FATEFate Therapeutics, Inc.Mar 2026-$77K USD-140.3%—0.0%
ALECAlector, Inc.Mar 2026-$104K USD-154.5%—0.0%
NKTXNkarta, Inc.Mar 2026-$130K USD-119.9%—0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026-$161K USD-600.0%—0.1%
VORVor Biopharma Inc.Mar 2026-$706K USD-3169.6%—0.1%
Peer median (excluding ALEC) —-154.2%—0.0%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents329.15M154.32M74.56M33.02M65.8M
Short-term Investments406.1M558.53M474.31M380.38M190.22M
Net Receivables7.39M2.59M000
Inventory00000
Other Current Assets0016.95M11.42M10.43M
Total Current Assets749.71M726.44M565.81M424.82M266.45M
Property, Plant & Equipment (Net)57.9M53.33M47.06M37.1M24.55M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets7.05M7.88M8.96M6.39M2.23M
Total Non-current Assets64.95M61.21M56.02M43.49M26.79M
Total Assets814.66M787.65M621.83M468.3M293.24M
Account Payables4.75M4.19M3.78M2.22M1.69M
Short-term Debt0000366K
Tax Payables00000
Deferred Revenue90.8M48.23M82.98M23.66M6.68M
Other Current Liabilities11.66M12.76M54.74M54.55M24.39M
Total Current Liabilities139.56M93.81M177.95M125.06M69.5M
Long-term Debt0009.39M9.32M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)334.42M443.37M210.85M172.17M164.54M
Other Non-current Liabilities158K759K68.42M10.51M1.74M
Total Non-current Liabilities374.38M479.4M309.72M216.44M193.09M
Total Liabilities513.93M573.21M487.67M341.5M262.59M
Common Stock8K8K8K9K11K
Retained Earnings(446.38M)(579.69M)(710.08M)(829.13M)(972.06M)
Accumulated OCI(943K)(4.58M)184K261K166K
Other Stockholders Equity00000
Minority Interest00000
Total Equity300.72M214.44M134.16M126.8M30.65M
Total Debt47.6M43.33M38.92M42.52M36.23M
Net Debt(281.55M)(111M)(35.64M)9.5M(29.57M)

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.